Tyers Asset Management LLC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 39.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 27,896 shares of the biotechnology company’s stock after selling 18,150 shares during the quarter. Tyers Asset Management LLC’s holdings in United Therapeutics were worth $3,274,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc lifted its position in shares of United Therapeutics by 1.7% in the 3rd quarter. Vanguard Group Inc now owns 3,775,103 shares of the biotechnology company’s stock worth $482,760,000 after purchasing an additional 61,361 shares during the period. Rhumbline Advisers increased its stake in shares of United Therapeutics by 37.7% in the 4th quarter. Rhumbline Advisers now owns 109,108 shares of the biotechnology company’s stock worth $11,882,000 after acquiring an additional 29,895 shares in the last quarter. First Mercantile Trust Co. increased its stake in shares of United Therapeutics by 47.8% in the 4th quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 110 shares in the last quarter. Dupont Capital Management Corp increased its stake in shares of United Therapeutics by 23.9% in the 4th quarter. Dupont Capital Management Corp now owns 7,186 shares of the biotechnology company’s stock worth $783,000 after acquiring an additional 1,386 shares in the last quarter. Finally, Financial Gravity Companies Inc. bought a new position in shares of United Therapeutics in the 4th quarter worth about $44,000. Institutional investors own 96.47% of the company’s stock.

Several research analysts recently issued reports on the stock. ValuEngine lowered shares of United Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. UBS Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and decreased their price target for the stock from $115.00 to $94.00 in a research note on Friday, May 17th. They noted that the move was a valuation call. BidaskClub lowered shares of United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 15th. Credit Suisse Group upgraded shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $98.00 price target for the company in a research note on Thursday, May 9th. Finally, Wedbush set a $273.00 price target on shares of United Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $129.00.

NASDAQ:UTHR traded down $0.41 on Wednesday, reaching $80.35. 16,788 shares of the stock traded hands, compared to its average volume of 535,905. The firm has a market cap of $3.59 billion, a P/E ratio of 5.99 and a beta of 1.15. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.84 and a current ratio of 7.19. United Therapeutics Co. has a 12 month low of $80.10 and a 12 month high of $130.00.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($13.96). The firm had revenue of $362.70 million for the quarter, compared to the consensus estimate of $335.72 million. United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The firm’s revenue for the quarter was down 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.76 earnings per share. On average, equities research analysts predict that United Therapeutics Co. will post -5.03 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Marea Informative and is owned by of Marea Informative. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.mareainformativa.com/news/2019/06/12/united-therapeutics-co-nasdaquthr-shares-sold-by-tyers-asset-management-llc.html.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: What is the Coverage Ratio?

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.